Results 231 to 240 of about 24,933,173 (248)

Specific dephosphorylation of Janus Kinase 2 by protein tyrosine phosphatases

PROTEOMICS, 2014
Many protein kinases are activated through phosphorylation of an activation loop thereby turning on downstream signaling pathways. Activation of JAK2, a nonreceptor tyrosine kinase with an important role in growth factor and cytokine signaling, requires phosphorylation of the 1007 and 1008 tyrosyl residues.
Jianzhuo, Li, Xidong, Liu, Huiying, Chu, Xueqi, Fu, Tianbao, Li, Lianghai, Hu, Shu, Xing, Guohui, Li, Jingkai, Gu, Zhizhuang Joe, Zhao   +9 more
openaire   +2 more sources

Downregulation of Chloride Channel ClC-2 by Janus Kinase 3

The Journal of Membrane Biology, 2014
Janus kinase-3 (JAK3) fosters proliferation and counteracts apoptosis of lymphocytes and tumor cells. The gain of function mutation (A572V)JAK3 has been discovered in acute megakaryoplastic leukemia. JAK3 is inactivated by replacement of lysine by alanine in the catalytic subunit ((K855A)JAK3).
Jamshed, Warsi, Bernat, Elvira, Zohreh, Hosseinzadeh, Ekaterina, Shumilina, Florian, Lang   +4 more
openaire   +2 more sources

Modulation of Janus kinase 2 by p53 in ovarian cancer cells

Biochemical and Biophysical Research Communications, 2004
The constitutive activation of the Janus kinase 2 (JAK2) and mutation of the p53 tumor suppressor are both detected in human cancer. We examined the potential regulation of JAK2 phosphorylation by wild-type (wt) p53 in human ovarian cancer cell lines, Caov-3 and MDAH2774, which harbor mutant form of p53 tumor suppressor gene and high levels of ...
Thomas, Reid, Xiaohong, Jin, Hui, Song, Huai-Jing, Tang, R Kevin, Reynolds, Jiayuh, Lin   +5 more
openaire   +2 more sources

Inhibition of Janus kinase 2 by cyclometalated rhodium complexes

MedChemComm, 2012
Cyclometalated rhodium complexes were synthesized and evaluated as JAK2 metal-based inhibitors. Complexes 1 and 2 inhibited JAK2 enzyme phosphorylation activity, reduced JAK2 autophosphorylation in cellulo and exhibited cytotoxicity towards HEL cancer cells. To our knowledge, these are the first two examples of metal-based inhibitors of JAK2.
Chung-Hang Leung, Hui Yang, Victor Pui-Yan Ma, Daniel Shiu-Hin Chan, Hai-Jing Zhong, Ying-Wei Li, Wang-Fun Fong, Dik-Lung Ma   +7 more
openaire   +1 more source

Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors

Bioorganic & Medicinal Chemistry, 2017
Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized.
Yazhou, Wang, Wei, Huang, Minhang, Xin, Pan, Chen, Li, Gui, Xinge, Zhao, Feng, Tang, Jia, Wang, Fei, Liu   +8 more
openaire   +2 more sources

Role of Janus Kinase Inhibitors in Therapy of Psoriasis

Journal of Clinical Medicine, 2021
Andrzej Pawlik, Sylwia Słuczanowska-Głąbowska, Kamila Szumilas   +2 more
exaly  

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

Journal of Inflammation Research, 2023
Jin-Ying Lin
exaly  

Structural basis of Janus kinase trans-activation

Cell Reports, 2023
Kenan Garcia, Stevan R Hubbard, Caleb R. Glassman   +2 more
exaly  

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

Journal of the American Academy of Dermatology, 2023

exaly  

Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis

European Journal of Gastroenterology & Hepatology, 2008
COLAIZZO D, AMITRANO L, GUARDASCIONE MA, BALZANO A, MARGAGLIONE, MAURIZIO   +4 more
openaire   +2 more sources